Compensation of the AKT Signaling by ERK Signaling in Transgenic Mice Hearts Overexpressing TRIM72
Overview
Authors
Affiliations
The AKT and ERK signaling pathways are known to be involved in cell hypertrophy, proliferation, survival and differentiation. Although there is evidence for crosstalk between these two signaling pathways in cellulo, there is less evidence for cross talk in vivo. Here, we show that crosstalk between AKT and ERK signaling in the hearts of TRIM72-overexpressing transgenic mice (TRIM72-Tg) with alpha-MHC promoter regulates and maintains their heart size. TRIM72, a heart- and skeletal muscle-specific protein, downregulates AKT-mTOR signaling via IRS-1 degradation and reduces the size of rat cardiomyocytes and the size of postnatal TRIM72-Tg hearts. TRIM72 expression was upregulated by hypertrophic inducers in cardiomyocytes, while IRS-1 was downregulated by IGF-1. TRIM72 specifically regulated IGF-1-dependent AKT-mTOR signaling, resulting in a reduction of the size of cardiomyocytes. Postnatal TRIM72-Tg hearts were smaller than control-treated hearts with inhibition of AKT-mTOR signaling. However, adult TRIM72-Tg hearts were larger than of control despite the suppression of AKT-mTOR signaling. Activation of ERK, PKC-α, and JNK were observed to be elevated in adult TRIM72-Tg, and these signals were mediated by ET-1 via the ET receptors A and B. Altogether, these results suggest that AKT signaling regulates cardiac hypertrophy in physiological conditions, and ERK signaling compensates for the absence of AKT signaling during TRIM72 overexpression, leading to pathological hypertrophy.
Trim72 is a major host factor protecting against lethal Candida albicans infection.
Tan W, Liu J, Yu R, Zhao P, Liu Y, Lu Q PLoS Pathog. 2024; 20(11):e1012747.
PMID: 39585917 PMC: 11627414. DOI: 10.1371/journal.ppat.1012747.
MG53/TRIM72: multi-organ repair protein and beyond.
Wang Y, An Z, Li J, Dong Z, Jin W Front Physiol. 2024; 15:1377025.
PMID: 38681139 PMC: 11046001. DOI: 10.3389/fphys.2024.1377025.
Advances in the Study of MG53 in Cardiovascular Disease.
Liu S, Zhao Q, Li W, Zhao J Int J Gen Med. 2023; 16:6073-6082.
PMID: 38152078 PMC: 10752033. DOI: 10.2147/IJGM.S435030.
Is MG53 a potential therapeutic target for cancer?.
Du Y, Li T, Yi M Front Endocrinol (Lausanne). 2023; 14:1295349.
PMID: 38033997 PMC: 10684902. DOI: 10.3389/fendo.2023.1295349.
Cardiac effects and clinical applications of MG53.
Zhong W, Benissan-Messan D, Ma J, Cai C, Lee P Cell Biosci. 2021; 11(1):115.
PMID: 34183055 PMC: 8240287. DOI: 10.1186/s13578-021-00629-x.